Recent Updates
Recently added Catalysts

EIK1004-001

Phase 1

Advanced Solid Tumors | Small molecule | Oncology |Eikon Therapeutics, Inc.|Last Updated: Aug 19, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment130
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06907043A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.PHASE1 RECRUITING 130Apr 30, 2025Dec 1, 2028Aug 19, 202510 United States, Australia +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants who experience a Dose-Limiting Toxicity (DLT)
(Timeframe: up to 28 days)

A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT will be reported.

Number of participants with adverse events, treatment emergent adverse events or serious adverse events
(Time Frame: 1 month post last dose of EIK1004 (IMP1707)

Number of participants reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters

Secondary Endpoints
Pharmacokinetic parameters of EIK1004 (IMP1707)
Through study completion, up to 3 years
Objective Response (OR)
Through study completion, up to 3 years
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part 1EXPERIMENTALEIK1004 (IMP1707) monotherapy; oral tablet(s) daily (except for the single-dose period). Participants will receive escalating doses of EIK1004 (IMP1707) until progressive disease or discontinuation.
Interventions
NameTypeDescription
EIK1004-001 (IMP1707-001)DRUGPARP1 selective inhibitor
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 89 Years
SexALL
Healthy VolunteersNo
Study Sites10

• Breast cancer: must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemothe...

Countries:United StatesAustraliaChina
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06907043primaryCompletionDate: changed
LOWMay 24, 2026NCT06907043studyFirstPostDate: changed